Prognostic Values of Serum Tenascin-C in Patients with Ischaemic Heart Disease and Heart Failure

Heart Lung and Circulation

Volumn 22, Issue 3, 2013, Pages 184-187

  Yao, Heng Chen ^a   Han, Qian Feng ^a   Zhao, Ai Ping ^a   Yao, Dao Kuo ^b   Wang, Le Xin ^a,c  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CHARLES STURT UNIVERSITY   (Australia)

Author keywords

B type natriuretic peptide; Heart failure; Procollagen; Tenascin C

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROCOLLAGEN; PROCOLLAGEN 3; TENASCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HOSPITAL READMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION FUNCTION TEST; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; UPREGULATION;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLLAGEN TYPE III; CONFIDENCE INTERVALS; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TENASCIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84875365187     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2012.10.005     Document Type: Article

References (27)

1. Felker G.M., Shaw L.K., O'Connor C.M. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002, 39:210-218.
2. Gheorghiade M., Sopko G., De Luca L., Velazquez E.J., Parker J.D., Binkley P.F., et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006, 114:1202-1213.
3. Golledge J., Clancy P., Maguire J., Lincz L., Koblar S. The role of tenascin c in cardiovascular disease. Cardiovasc Res 2011, 92:19-28.
4. Ballard V.L., Sharma A., Duignan I., Holm J.M., Chin A., Choi R., et al. Vascular tenascin-c regulates cardiac endothelial phenotype F neovascularization. FASEB J 2006, 20:717-719.
5. Wallner K., Li C., Shah P.K., Fishbein M.C., Forrester J.S., Kaul S., et al. Tenascin-c is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999, 99:1284-1289.
6. Sato A., Aonuma K., Imanaka-Yoshida K., Yoshida T., Isobe M., Kawase D., et al. Serum tenascin-c might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006, 47:2319-2325.
7. Schenke-Layland K., Stock U.A., Nsair A., Xie J., Angelis E., Fonseca C.G., et al. Cardiomyopathy is associated with structural remodelling of heart valve extracellular matrix. Eur Heart J 2009, 30:2254-2265.
8. Franz M., Brehm B.R., Richter P., Gruen K., Neri D., Kosmehl H., et al. Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-c splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human sip format antibodies. J Mol Histol 2010, 41:39-50.
9. Schumann C., Lepper P.M., Frank H., Schneiderbauer R., Wibmer T., Kropf C., et al. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers 2010, 15:523-532.
10. Terasaki F., Okamoto H., Onishi K., Sato A., Shimomura H., Tsukada B., et al. Higher serum tenascin-c levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 2007, 71:327-330.
11. Aso N., Tamura A., Nasu M. Circulating tenascin-c levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2004, 94:1468-1470.
12. Fujimoto N., Onishi K., Sato A., Terasaki F., Tsukada B., Nozato T., et al. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Cardiac Fail 2009, 15:898-905.
13. Kitaoka H., Kubo T., Baba Y., Yamasaki N., Matsumura Y., Furuno T., et al. Serum tenascin-C levels as a prognostic biomarker of heart failure events in patients with hypertrophic cardiomyopathy. J Cardiol 2012, 59:209-214.
14. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., et al. Esc Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
15. Ma Z.S., Ma S.J., Dong M.F., Wang J.T., Wang L.X. Effect of captopril on pulmonary artery pressure following corrective surgery for tetralogy of fallot. J Card Surg 2009, 24:553-557.
16. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
17. Hasegawa M., Hirata H., Sudo A., Kato K., Kawase D., Kinoshita N., et al. Tenascin-c concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol 2004, 31:2021-2026.
18. Ren H.Z., Zhang X.S., Wang L.X. Effect of coronary revascularization on serum collagen biomarkers and left ventricular remodeling in patients with acute myocardial infarction. Heart Lung 2012, 41:344-349.
19. Morimoto S., Imanaka-Yoshida K., Hiramitsu S., Kato S., Ohtsuki M., Uemura A., et al. Diagnostic utility of tenascin-c for evaluation of the activity of human acute myocarditis. J Pathol 2005, 205:460-467.
20. Tamaoki M., Imanaka-Yoshida K., Yokoyama K., Nishioka T., Inada H., Hroe M., et al. Tenascin-c regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005, 167:71-80.
21. Voors A.A., Petrie C.J., Petrie M.C., Charlesworth A., Hillege H.L., Zijlstra F., et al. Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure. Eur Heart J 2005, 26:1759-1764.
22. Kelder J.C., Cowie M.R., McDonagh T.A., Hardman S.M., Grobbee D.E., Cost B., et al. Quantifying the added value of bnp in suspected heart failure in general practice: an individual patient data meta-analysis. Heart 2011, 97:959-963.
23. Poulsen S.H., Host N.B., Jensen S.E., Egstrup K. Relationship between serum amino-terminal propeptide of type iii procollagen and changes of left ventricular function after acute myocardial infarction. Circulation 2000, 101:1527-1532.
24. Uusimaa P., Risteli J., Niemela M., Lumme J., Ikaheimo M., Jounela A., et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997, 96:2565-2572.
25. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
26. Iraqi W., Rossignol P., Angioi M., Fay R., Nuee J., Ketelslegers J.M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (ephesus) study. Circulation 2009, 119:2471-2479.
27. Radauceanu A., Moulin F., Djaballah W., Marie P.Y., Alla F., Dousset B., et al. Residual stress ischaemia is associated with blood markers of myocardial structural remodelling. Eur J Heart Fail 2007, 9:370-376.